Pamrevlumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pamrevlumab
Accession Number
DB14952
Description

Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • FG-3019

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Pamrevlumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pamrevlumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Pamrevlumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Pamrevlumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pamrevlumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pamrevlumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Pamrevlumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Pamrevlumab.
AvelumabThe risk or severity of adverse effects can be increased when Avelumab is combined with Pamrevlumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
QS5F6VTS0O
CAS number
946415-13-0

References

General References
Not Available
Wikipedia
Pamrevlumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentPancreatic Cancer Non-resectable1
2Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)2
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2TerminatedTreatmentDiabetic Kidney Disease / Nephropathy, Diabetic / Type 2 Diabetes Mellitus1
2TerminatedTreatmentLiver Fibrosis Due to Chronic Hepatitis B Infection1
1CompletedTreatmentDiabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:37 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates